CONMED CFO granted options and RSU awards

Gallagher John E reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Gallagher John E reported acquisition or exercise transactions in this Form 4 filing.

CONMED Corp Executive Vice President & CFO John E. Gallagher received equity awards on July 15, 2026, including 30,536 stock options to purchase common shares at $42.79 per share and RSU grants of 26,875 and 35,054 shares under the Company’s 2025 Long-Term Incentive Plan.

The RSUs generally vest over three years (33%, 33%, 34% annually), while the stock options generally vest over four years in equal 25% installments, beginning one year after the grant date, and expire on July 15, 2036.

Insider Trade Summary

Grant/Award: 92,465 shares

Grant/Award 3 txns

Insider Gallagher John E

Role Executive Vice President & CFO

Type	Security	Shares	Price	Value
Grant/Award	RSUs (Restricted Stock Units) F1	35,054	$0.00	$0.00
Grant/Award	RSUs (Restricted Stock Units) F1	26,875	$0.00	$0.00
Grant/Award	Options To Purchase Common Stock F2	30,536	$0.00	$0.00

Holdings After Transaction: RSUs (Restricted Stock Units) — 61,929 contracts (Direct); Options To Purchase Common Stock — 30,536 contracts (Direct)

Footnotes (2)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting over a three-year period with the first 33% of the RSUs vesting one year after the grant date, 33% second year and 34% third year.
2. F2. The stock options were granted under CONMED Corporation's 2025 Long-Term Incentive Plan, with the stock options generally vesting in equal amounts over a four-year period with the first 25% of the stock options vesting one year after the grant date.

Key Figures

Stock options granted: 30,536 options Option exercise price: $42.79 per share RSUs granted (tranche 1): 26,875 RSUs +2 more

5 metrics

Stock options granted 30,536 options Grant to Executive Vice President & CFO on July 15, 2026

Option exercise price $42.79 per share Exercise price for 30,536 options granted July 15, 2026

RSUs granted (tranche 1) 26,875 RSUs Restricted stock units referencing common stock, granted July 15, 2026

RSUs granted (tranche 2) 35,054 RSUs Additional restricted stock units referencing common stock, granted July 15, 2026

Option expiration date July 15, 2036 Expiration for stock options granted to the CFO under 2025 Long-Term Incentive Plan

Key Terms

Restricted Stock Units, Long-Term Incentive Plan, stock options, vesting

4 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Long-Term Incentive Plan financial

"subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan"

A long-term incentive plan is a company program that pays executives or employees with stock, options, or cash tied to multi-year performance goals, where the rewards become theirs only after meeting conditions over time. Think of it as a delayed bonus or retirement-style reward that aligns employees’ interests with shareholders by encouraging them to boost long-term value; investors watch these plans because they affect pay costs, share dilution and management incentives.

stock options financial

"The stock options were granted under CONMED Corporation's 2025 Long-Term Incentive Plan"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

vesting financial

"generally vesting over a three-year period with the first 33% of the RSUs vesting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did CNMD’s CFO John Gallagher receive on July 15, 2026?

On July 15, 2026, John E. Gallagher received 30,536 stock options with a $42.79 exercise price and two RSU grants covering 26,875 and 35,054 shares of CONMED common stock, all under the Company’s 2025 Long-Term Incentive Plan.

What are the terms of the new CONMED (CNMD) stock options granted to the CFO?

The grant consists of 30,536 stock options to purchase CONMED common stock at an exercise price of $42.79 per share. These options generally vest over four years in equal 25% installments, beginning one year after the July 15, 2026 grant date, and expire July 15, 2036.

How do the new RSUs for CNMD’s CFO vest over time?

The RSU awards of 26,875 and 35,054 shares each represent rights to receive one CONMED common share per unit. They generally vest over three years, with 33% vesting after one year, another 33% after two years, and 34% after three years.

Under which plan were the CNMD equity awards to the CFO granted?

Both the stock options and RSUs granted to John E. Gallagher were issued under CONMED’s 2025 Long-Term Incentive Plan. This plan governs the terms, including vesting schedules, for the executive’s equity-based compensation awards reported in this insider transaction disclosure.

Does this CNMD insider report show any stock sales by the CFO?

No. The reported transactions are all acquisitions of derivative securities: grants of stock options and RSUs. There are no sales or other dispositions of CONMED common stock or derivatives by John E. Gallagher disclosed in this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 03:09 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gallagher John E

(Last) (First) (Middle)

C/O CONMED CORPORATION

11311 CONCEPT BOULEVARD

(Street)

LARGO FLORIDA 33773

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CONMED Corp [ CNMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President & CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
RSUs (Restricted Stock Units)	$0	07/15/2026		A		35,054		(1)	07/15/2036	Common Stock	35,054	$0	35,054	D
RSUs (Restricted Stock Units)	$0	07/15/2026		A		26,875		(1)	07/15/2036	Common Stock	26,875	$0	61,929	D
Options To Purchase Common Stock	$42.79	07/15/2026		A		30,536		(2)	07/15/2036	Common Stock	30,536	$0	30,536	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting over a three-year period with the first 33% of the RSUs vesting one year after the grant date, 33% second year and 34% third year.

2. The stock options were granted under CONMED Corporation's 2025 Long-Term Incentive Plan, with the stock options generally vesting in equal amounts over a four-year period with the first 25% of the stock options vesting one year after the grant date.

	/s/ Thomas Fistek for John Gallagher by Power of Attorney	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)